Just $7/month gets you a limited edition KaiPA pint glass. Plus bragging rights that you support independent journalism.
Donate today to get yours!
Marketplace Morning Report for Thursday, April 11, 2013
Share Now on:
Segments From this episode
Biogen Idec, a Massachusetts-based biotech company, is hoping its new multiple sclerosis drug Tecfidera will eventually bring in the hundreds of millions of dollars it cost to develop — at least before a generic comes along and copies it. CEO George Scangos discusses his company’s development process and pricing strategy. A new report from the research firm IDC says personal computer sales are falling fast all around the world. And in Phoenix, Arizona, new signs of a real estate bubble are emerging.